Protealis Launches Four New Soybean Varieties and Expands Commercial Reach in Europe
First-Time Registrations in France and Germany
Ghent (Belgium), 22 March 2024 – Protealis, a leading seeds and seed technologies developer for sustainable plant proteins, today announces the launch of four new soy seed varieties. The company’s portfolio expansion includes first-time registrations in France and Germany. This underlines Protealis’ dedication to commercially expand its footprint in Europe, as announced on 23 January 2024 upon the successful conclusion of its EUR 22 million B-Round funding. All newly registered soybean varieties are from the very early 000 category, tailored to thrive in the colder, northern European climate. This aligns with Protealis’ mission to develop and commercialise legume crops that are better adapted to the European environment, facilitating the adoption of local soybean to novel and rapidly growing markets in Northern-Europe.
Protealis’ four new soy varieties - PRO Vesuvio, PRO Helicon, PRO Taranaki and PRO Jacinto – have been bred specifically to deliver both high yield and high protein content despite the shorter (colder) growing season in Northern Europe. These are essential traits for European farmers looking to switch from traditional break crops such as canola, to a more sustainable and profitable legume crop. The official variety trials in France, Belgium and Germany confirmed such enhanced performance in yield and/or protein compared to the commercially relevant checks[1]. The new varieties complement the existing soy seed portfolio of Artemis and Hermes, which immediately topped the official charts in Belgium upon launch in 2021.
Benjamin Laga, CEO of Protealis, commented: "We are excited to launch no less than four new soybean varieties this year, including first-time registrations in France and Germany. Registration procedures are rigorous and include the need to demonstrate both high performance and uniqueness of a variety. As such, the launch of these four new Protealis soybean varieties clearly demonstrates the high-quality product offering we are building for European farmers. As from now, we will be presenting these new varieties to several large B2B players in key expanding soybean markets, looking for premium soybean varieties for both the food and feed market.”
According to Donau Soja, a non-profit European independent multistakeholder organisation, the soy area in Europe has doubled in the past 10 years to over 5 million soy ha recorded in Europe in 2023[2], driven by its many benefits. Legume crops such as soy are an excellent source of protein for both the food and feed market. Soy can be grown sustainably since it does not require nitrogen fertilization. With their fibrous roots, legumes improve soil quality and are an excellent addition for farmers in any crop rotation and indispensable for regenerative agriculture.
In addition to soy, Protealis continues to advance its yellow pea breeding program and is investing in the development of supporting technology platforms focused on the prediction of for example crop yield and quality, based on a combination genetic fingerprinting and AI. This will allow the company to further accelerate the introduction of new and better protein crop varieties to the market.
*** END***
More information:
Renate Degrave
Head of Communications and Marketing Protealis
renate.degrave@protealis.com | +32 471 53 60 64
About Protealis
Protealis develops superior plant protein seeds and seed technologies, optimized for the European soil and climate. Being at the forefront of sustainable agriculture, Protealis aims to empower European farmers with sustainable and resilient alternatives to traditional protein sources by developing legume seed solutions with enhanced crop yield and protein levels, while at the same time minimizing the ecological footprint. By addressing the growing demand for more plant-based protein sources, the company is committed to contribute to more sustainable food systems. Today, Protealis is a commercial-stage company with six early maturity soy varieties on the market and is headquartered in the biotechnology cluster in Ghent, Belgium. More info on www.protealis.com, LinkedIn or facebook.
Data protection is important to us. You are receiving this publication on the legal basis of Article 6 para 1 lit. f GDPR ("legitimate interest"). However, if you do not wish to receive further information about Protealis, email us at info@protealis.com and we will no longer process your details for this purpose. You can also find further details in our privacy statement on www.protealis.com.
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Protealis’ (‘the Company’) or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
[1] Official trial results: PRO Vesuvio and PRO Helicon in France (CTPS); PRO Vesuvio, PRO Helicon and PRO Jacinto in Belgium; PRO Taranaki in Germany